PROLUNG
Prolung is a Biotechnology company that offers innovative predictive analytics technology.
PROLUNG
Social Links:
Industry:
Biotechnology Health Care Life Science
Founded:
2004-01-01
Address:
Salt Lake City, Utah, United States
Country:
United States
Website Url:
http://www.prolunginc.com
Total Employee:
11+
Status:
Active
Contact:
801-204-9623
Total Funding:
182 K USD
Technology used in webpage:
Pinterest Reddit
Similar Organizations
Afrigen
Afrigen is a biotechnology company that offers bulk water soluble, nanosomal CBD, and encapsulation technologies.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Renovacor
Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapy‑based treatments for cardiovascular disease.
Current Employees Featured
Founder
Official Site Inspections
http://www.prolunginc.com
- Host name: a2aa9ff50de748dbe.awsglobalaccelerator.com
- IP address: 3.33.130.190
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Prolung"
Prolung - Crunchbase Company Profile & Funding
Prolung is a Biotechnology company that offers innovative predictive analytics technology.See details»
Prolung Inc - Company Profile and News - Bloomberg Markets
Company profile page for Prolung Inc including stock price, company news, executives, board members, and contact informationSee details»
ProLung, Inc. Announces Organizational Changes to Sharpen …
SALT LAKE CITY, UT / ACCESSWIRE / September 13, 2018 / ProLung, Inc. (“ProLung” or the “Company”) today announced the Company is taking significant steps to better align its …See details»
ProLung, Inc. Announces Organizational Changes to Sharpen …
Sep 13, 2018 SALT LAKE CITY, UT / ACCESSWIRE / September 13, 2018 / ProLung, Inc. ("ProLung" or the "Company") today announced the Company is taking significant steps to …See details»
ProLung Announces Corporate Name Change to IONIQ Sciences …
May 27, 2020 IONIQ Sciences remains fully committed to gaining U.S. FDA regulatory clearance and subsequently commercializing the IONIQ ProLung Test™ for lung cancer. The ProLung …See details»
ProLung, Inc. Company Profile | Salt Lake City, UT | Competitors ...
Find company research, competitor information, contact details & financial data for ProLung, Inc. of Salt Lake City, UT. Get the latest business insights from Dun & Bradstreet.See details»
ProLung Test Granted ‘Breakthrough Device’ Designation by the FDA
Feb 13, 2020 SALT LAKE CITY, UT / ACCESSWIRE / February 13, 2020 / ProLung, Inc. ("ProLung" or the "Company"), which has developed a cutting edge predictive analytic that …See details»
ProLung, Inc. - VentureRadar
ProLung is a medical technology company specializing in innovative predictive analytics technology and non-invasive test for the risk stratification of indeterminate pulmonary nodules …See details»
ProLungdx: Contact Details and Business Profile - RocketReach
ProLungdx is a Biotechnology, Lung Cancer, and Science and Engineering company_reader located in Salt Lake City, Utah with 14 employees. Find top employees, contact details and …See details»
ProLung - Products, Competitors, Financials, Employees, …
ProLung is a medical device company that has developed and tested a non-invasive early diagnostics of lung cancer to save or extend lives through the early risk stratification of lung …See details»
ProLung Test Granted ‘Breakthrough Device’ Designation by the FDA
Feb 13, 2020 Mr. Jared Bauer, Chief Executive Officer, stated, "The Breakthrough Device designation from the FDA is a momentous achievement for ProLung ® and our patented …See details»
ProLung Announces Corporate Name Change to IONIQ Sciences …
May 27, 2020 SALT LAKE CITY, UT / ACCESSWIRE / May 27, 2020 / IONIQ Sciences Inc. ("IONIQ Sciences" or the "Company"), which is changing the cancer landscape with a modern …See details»
ProLung, Inc. Announces Large Clinical Validation Trial Results of …
Oct 3, 2019 The study was sponsored by ProLung China and executed by its subsidiary, ProLung Biotech Wuxi, under the supervision of a Clinical Research Organization (CRO).See details»
ProLung, Inc. Announces Closing of Private Placement Transaction …
May 11, 2017 "ProLung is pleased to announce the successful closing of its private placement," said Steven Eror, President and CEO of ProLung. "The demand for ProLung stock …See details»
Prolung Announces an Intellectual Property and Regulatory Update
Oct 11, 2018 ProLung is currently making careful final preparations to break the data blind from its pivotal clinical validation Study (PL-208) and is taking full advantage of new opportunities to …See details»
ProLung Selected to Participate at Upcoming Cavendish Global …
May 4, 2017 "ProLung recently became a member of Cavendish Global and is looking forward to its participation in the organization.See details»
ProLung Announces Fully Subscribed Private Placement of $3.3 …
May 22, 2020 Jared Bauer, ProLung CEO, stated, "ProLung is pleased to announce the fully subscribed private placement managed by our investment bankers at Weild & Co. Successful …See details»
Technical ProLung® System PL1000 Data Sheet the risk strat
Www.prolunginc.com Aluminum, sheet steel 80 kg Drawer w/ lock and internal mounting platform USB hub for ProLung Test Scan Key Probe holder Cable winder Push handle Shelf and …See details»
Prolung, Inc. Presents Highest Combined Sensitivity And Specificity ...
Oct 31, 2019 Mr. Jared Bauer, ProLung CEO, stated, "These trial results are the highest combined sensitivity and specificity values for a truly non-invasive solution that is pursuing …See details»
Prolung, Inc. Presents Highest Combined Sensitivity And Specificity ...
The trial utilized key modifications to the ProLung System protocol and was led by Professor Chunxue Bai from Fudan University, who is also the President of the ISRD & ATS Joint …See details»